DDInter624 DDInter817
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Arsenic trioxide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Gilteritinib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may lead to a major life threatening interaction when taken with Gilteritinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Arsenic trioxide (Compound) and Arsenic trioxide may lead to a major life threatening interaction when taken with Gilteritinib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Gilteritinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Gilteritinib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib